27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
AbbVie Inc (NYSE: ABBV) reported another beat and raise quarter, with the 2Q revenue and EPS beating the consensus expectations.
Barclays’ Geoff Meacham maintains an Equal-Weight rating on the company, with a price target of $68.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Meacham mentioned that while execution remains consistent, 2H16 appears to be “noisy.”
2Q Results
AbbVie reported robust 2Q revenue at $6.4 billion, with EPS of $1.26, beating the consensus forecasts.
Once again, Humira proved to be the primary driver of the results, with both international and U.S. revenues showing upside, although Imbruvica has become the company’s second largest product line and an incrementally crucial part of the revenue trajectory.
Guidance Raised
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
AbbVie raised its 2016 guidance, now expecting total revenue to come in at $26 billion, with U.S. Humira expected to grow over 20 percent and international sales growing in the mid-single digits, ex-FX.
The company also raised its EPS guidance range from $4.62–$4.82 to $4.74–$4.83, while guiding to 3Q16 EPS of $1.18–$1.20.
Near-Term Expectations
“While we have high conviction that AbbVie can hit its increased 2016 guidance, we also see likely upcoming headlines related to adalimumab biosimilars and related litigation remaining the focal point over the near term,” Meacham stated.
Although the analyst does not expect a biosimilar competitor to be launched in the near term, further de-risking of the company’s mid-stage pipeline assets and/or business development, which could increase visibility into revenue diversification, were likely to remain key multiple expansion drivers.
The revenue and EPS estimates for 2016 have been raised.
Full ratings data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.